Skip to main content
Erschienen in: International Journal of Hematology 4/2010

01.05.2010 | Original Article

Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes

verfasst von: Tsutomu Shichishima, Kazuhiko Ikeda, Naoto Takahashi, Junichi Kameoka, Katsushi Tajima, Kazunori Murai, Yoshiko Tamai, Akiko Shichishima-Nakamura, Kazuko Akutsu, Hideyoshi Noji, Masatoshi Okamoto, Hideo Kimura, Hideo Harigae, Takashi Oyamada, Toyomi Kamesaki, Yasuchika Takeishi, Kenichi Sawada

Erschienen in: International Journal of Hematology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

To clarify whether measurement of serum haptoglobin (Hp) has impact on understanding pathophysiology in bone marrow failure (BMF) syndromes, we investigated concentrations of serum Hp by nephelometric procedure in 156 Japanese patients with BMF, including 54 aplastic anemia (AA), 50 paroxysmal nocturnal hemoglobinuria (PNH), and 52 myelodysplastic syndromes (MDS) patients. The frequencies with low concentrations of serum Hp (<42 mg/dL) in PNH patients (98.0%) were significantly higher than those in AA (27.8%; P < 0.0001) and MDS (38.5%; P < 0.0001) patients. In AA patients, white blood cell (WBC), absolute neutrophil, and platelet counts were significantly decreased in the group (n = 15) with low concentrations of serum Hp than in that (n = 39) with normal concentrations of it, and WBC counts were positively correlated with concentrations of serum Hp, suggesting that WBC counts may affect the concentrations. In MDS patients, hemoglobin concentrations and serum iron were significantly decreased and increased, respectively, in the group (n = 20) with low concentrations of serum Hp than in that (n = 32) with normal concentrations of it, and the values of serum iron were inversely correlated with concentrations of serum Hp, suggesting that ineffective erythropoiesis may affect the concentrations. Several AA and MDS patients with low concentrations of serum Hp had Coombs-negative autoimmune hemolytic anemia determined by immunoradiometric assay. In conclusion, several factors in conjunction with pathophysiology contribute to decrease of serum Hp in BMF.
Literatur
1.
Zurück zum Zitat Young NS. The problem of clonality in aplastic anemia: Dr Dameshek’s riddle, restated. Blood. 1992;79:1385–92.PubMed Young NS. The problem of clonality in aplastic anemia: Dr Dameshek’s riddle, restated. Blood. 1992;79:1385–92.PubMed
2.
Zurück zum Zitat Shichishima T, Noji H. A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria. Hematology. 2002;7:211–27.CrossRefPubMed Shichishima T, Noji H. A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria. Hematology. 2002;7:211–27.CrossRefPubMed
3.
Zurück zum Zitat Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndromes. Blood. 2002;100:3897–902.CrossRefPubMed Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndromes. Blood. 2002;100:3897–902.CrossRefPubMed
4.
Zurück zum Zitat Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55−CD59− blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–14.CrossRefPubMed Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55CD59 blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–14.CrossRefPubMed
5.
Zurück zum Zitat Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.CrossRefPubMed Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.CrossRefPubMed
6.
Zurück zum Zitat Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure of haptoglobin and the haptoglobin–hemoglobin complex by electron microscopy. J Mol Biol. 1984;174:319–41.CrossRefPubMed Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure of haptoglobin and the haptoglobin–hemoglobin complex by electron microscopy. J Mol Biol. 1984;174:319–41.CrossRefPubMed
7.
Zurück zum Zitat Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.CrossRefPubMed Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.CrossRefPubMed
8.
Zurück zum Zitat Gabay C, Kushner I. Acute-phase proteins and other systemic response to inflammation. N Engl J Med. 1999;340:448–54.CrossRefPubMed Gabay C, Kushner I. Acute-phase proteins and other systemic response to inflammation. N Engl J Med. 1999;340:448–54.CrossRefPubMed
9.
Zurück zum Zitat Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–600.PubMed Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–600.PubMed
10.
Zurück zum Zitat Shinton NK, Richardson RW, Williams JDF. Diagnostic value of serum haptoglobin. J Clin Path. 1965;18:114–8.CrossRefPubMed Shinton NK, Richardson RW, Williams JDF. Diagnostic value of serum haptoglobin. J Clin Path. 1965;18:114–8.CrossRefPubMed
11.
Zurück zum Zitat Owen JA, Smith R, Padanyi R, Martin R. Serum haptoglobin in disease. Clin Sci. 1964;26:1–6.PubMed Owen JA, Smith R, Padanyi R, Martin R. Serum haptoglobin in disease. Clin Sci. 1964;26:1–6.PubMed
12.
Zurück zum Zitat International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718–21. International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718–21.
13.
Zurück zum Zitat Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogh HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324:1297–304.PubMedCrossRef Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogh HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324:1297–304.PubMedCrossRef
14.
Zurück zum Zitat Shichishima T, Terasawa T, Hashimoto C, Ohto H, Uchida T, Maruyama Y. Heterogeneous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol. 1991;78:545–50.CrossRefPubMed Shichishima T, Terasawa T, Hashimoto C, Ohto H, Uchida T, Maruyama Y. Heterogeneous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol. 1991;78:545–50.CrossRefPubMed
15.
Zurück zum Zitat Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:5332–40.PubMed Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:5332–40.PubMed
16.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The French-American-British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The French-American-British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed
17.
Zurück zum Zitat Harris NL, Jaffe ES, Dieboid J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed Harris NL, Jaffe ES, Dieboid J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed
18.
Zurück zum Zitat Lewis SM, Dacie JP. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–51.CrossRefPubMed Lewis SM, Dacie JP. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–51.CrossRefPubMed
19.
Zurück zum Zitat Shichishima T, Terasawa T, Saitoh Y, Hashimoto C, Ohto H, Maruyama Y. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol. 1993;85:378–86.CrossRefPubMed Shichishima T, Terasawa T, Saitoh Y, Hashimoto C, Ohto H, Maruyama Y. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol. 1993;85:378–86.CrossRefPubMed
20.
Zurück zum Zitat Okamoto M, Shichishima T, Noji H, Ikeda K, Nakamura A, Akutsu K, et al. High frequency of several PIG-A mutations in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2006;20:627–34.CrossRefPubMed Okamoto M, Shichishima T, Noji H, Ikeda K, Nakamura A, Akutsu K, et al. High frequency of several PIG-A mutations in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2006;20:627–34.CrossRefPubMed
21.
Zurück zum Zitat Ikeda K, Shichishima T, Yasukawa M, Nakamura-Shichishima A, Noji H, Akutsu K, et al. The role of Wilms’ tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone. Exp Hematol. 2007;35:618–26.CrossRefPubMed Ikeda K, Shichishima T, Yasukawa M, Nakamura-Shichishima A, Noji H, Akutsu K, et al. The role of Wilms’ tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone. Exp Hematol. 2007;35:618–26.CrossRefPubMed
22.
Zurück zum Zitat Van Lente F, Marchand A, Galen RS. Evaluation of a nephelometric assay for haptoglobin and its clinical usefulness. Clin Chem. 1979;25:2007–10.PubMed Van Lente F, Marchand A, Galen RS. Evaluation of a nephelometric assay for haptoglobin and its clinical usefulness. Clin Chem. 1979;25:2007–10.PubMed
23.
Zurück zum Zitat Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem. 1996;34:517–20.PubMed Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem. 1996;34:517–20.PubMed
24.
Zurück zum Zitat Kirch M, Genth E. Haptoglobin-serumkonzentration und haptoglobin-polymorphismus bei entzündlich-rheumatischen erkrankungen. Medwelt. 1990;41:319–24. Kirch M, Genth E. Haptoglobin-serumkonzentration und haptoglobin-polymorphismus bei entzündlich-rheumatischen erkrankungen. Medwelt. 1990;41:319–24.
25.
Zurück zum Zitat Jeje MO, Blajchman MA, Steeves K, Horsewood P, Kelton JG. Quantitation of red cell associated IgG using an immunoradiometric assay. Transfusion. 1984;24:473–6.CrossRefPubMed Jeje MO, Blajchman MA, Steeves K, Horsewood P, Kelton JG. Quantitation of red cell associated IgG using an immunoradiometric assay. Transfusion. 1984;24:473–6.CrossRefPubMed
26.
Zurück zum Zitat Kajii E, Oomi T, Miura S, Ikemoto N. A new approach for diagnosis of autoimmune hemolytic anemia. Jpn J Clin Hematol. 1993;35:336–40. Kajii E, Oomi T, Miura S, Ikemoto N. A new approach for diagnosis of autoimmune hemolytic anemia. Jpn J Clin Hematol. 1993;35:336–40.
27.
Zurück zum Zitat Kondo H, Kajii E, Oyamada T, Kasahara Y. Direct antiglobulin test negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Int J Hematol. 1998;68:439–43.CrossRefPubMed Kondo H, Kajii E, Oyamada T, Kasahara Y. Direct antiglobulin test negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Int J Hematol. 1998;68:439–43.CrossRefPubMed
28.
Zurück zum Zitat Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma. 2003;44:593–604.CrossRefPubMed Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma. 2003;44:593–604.CrossRefPubMed
29.
Zurück zum Zitat Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol. 2009;84:98–101.CrossRefPubMed Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol. 2009;84:98–101.CrossRefPubMed
30.
Zurück zum Zitat Theilgaard-Mönch K, Jacobsen LC, Nielsen WJ, Rasmussen T, Udby L, Gharib M, et al. Haptoglobin is synthesized during granulocytes, stored in specific granules, and released by neutrophils in response to activation. Blood. 2006;108:353–61.CrossRefPubMed Theilgaard-Mönch K, Jacobsen LC, Nielsen WJ, Rasmussen T, Udby L, Gharib M, et al. Haptoglobin is synthesized during granulocytes, stored in specific granules, and released by neutrophils in response to activation. Blood. 2006;108:353–61.CrossRefPubMed
31.
Zurück zum Zitat Buckstein R, Jang K, Friedlich J, Zhang L, Reis M, Chesney A, et al. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res. 2009;33:1313–8.CrossRefPubMed Buckstein R, Jang K, Friedlich J, Zhang L, Reis M, Chesney A, et al. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res. 2009;33:1313–8.CrossRefPubMed
32.
Zurück zum Zitat Marsh JCW, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70:1046–52.PubMed Marsh JCW, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70:1046–52.PubMed
33.
Zurück zum Zitat Tichelli A, Gratwohl A, Nissen C, Signer E, Gysi CS, Speck B. Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood. 1992;80:337–45.PubMed Tichelli A, Gratwohl A, Nissen C, Signer E, Gysi CS, Speck B. Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood. 1992;80:337–45.PubMed
Metadaten
Titel
Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes
verfasst von
Tsutomu Shichishima
Kazuhiko Ikeda
Naoto Takahashi
Junichi Kameoka
Katsushi Tajima
Kazunori Murai
Yoshiko Tamai
Akiko Shichishima-Nakamura
Kazuko Akutsu
Hideyoshi Noji
Masatoshi Okamoto
Hideo Kimura
Hideo Harigae
Takashi Oyamada
Toyomi Kamesaki
Yasuchika Takeishi
Kenichi Sawada
Publikationsdatum
01.05.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0559-z

Weitere Artikel der Ausgabe 4/2010

International Journal of Hematology 4/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.